EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 6 June 2024

To protect health resilience, Europe must continue to innovate

Read the article here

In the face of emerging health challenges, EFPIA is working to maintain Europe’s innovative edge.

In an interview with The Brussels Times, Peter Guenter, CEO Healthcare at Merck, and member of the board of EFPIA, set out the urgent needs for his sector, and for patients in the post-Covid era.

Keep health front and centre in the EU elections and beyond – a call from the Patient Think...
05 June 2024

The Patient Think Tank (PTT) is a forum for dialogue between the European research-based pharmaceutical industry and... Read more

Insights from EFPIA's Reliance Webinar
04 June 2024

On the 19th of March EFPIA have hosted a joint industry webinar on Reliance, providing a platform for information and... Read more

Incentives for the development of novel antimicrobials in the revision of the EU general pharmaceutical legislation

Antimicrobial resistance (AMR) is one of the most urgent global health threats of our time. The statistics are stark and alarming: in Europe alone, AMR claims 35,000 lives annually, with healthcare costs and productivity losses estimated at €1.5 billion each year. Without immediate action, these figures are poised to worsen in the years ahead. The revision of the EU general pharmaceutical legislation marks a significant milestone in the fight against AMR, with concrete solutions finally being discussed.

Register now for the IHI Call Days - Call 8

The IHI Call Days for IHI call 8 will run from 17 to 21 June 2024 online, and will provide potential applicants with the information they need to put together a strong proposal, and give them the opportunity to identify and meet partners for their consortia.

Learn more here.

Have you missed our latest event? Watch the recording!

Countdown to the EU HTA: how can we seize this opportunity to improve patient access to medicines?

What we are reading

Diabetes and cardiovascular disease causing profound clinical, psychosocial, socioeconomic...
On 05 June 2024 (Euractiv)

Cardiovascular disease related to diabetes is wrecking Europe’s public health budgets... Read more

The European Medicines Agency - Annual Report 2023
On 30 May 2024 (European Medicines Agency)

EMA's 2023 annual report offers insights into the initiatives and priority areas that guided the Agency's work in... Read more

Germany and France push for mega-deals in competition overhaul
On 28 May 2024 (POLITICO)

Important Projects of Common European Interest, which funnel money from several governments... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu